Role of adjuvant therapy in intermediate-risk cervical cancer patients – Subanalyses of the SCCAN study

• Published in: Gynecologic oncology Vol. 170; pp. 195 - 202
• Main Authors: Cibula, David, Akilli, Huseyin, Jarkovsky, Jiri, van Lonkhuijzen, Luc, Scambia, Giovanni, Meydanli, Mehmet Mutlu, Ortiz, David Isla, Falconer, Henrik, Abu-Rustum, Nadeem R., Odetto, Diego, Klát, Jaroslav, dos Reis, Ricardo, Zapardiel, Ignacio, Di Martino, Giampaolo, Presl, Jiri, Laky, Rene, López, Aldo, Weinberger, Vit, Obermair, Andreas, Pareja, Rene, Poncová, Renata, Mom, Constantijne, Bizzarri, Nicolò, Borčinová, Martina, Aslan, Koray, Salcedo Hernandez, Rosa Angélica, Fons, Guus, Benešová, Klára, Dostálek, Lukáš, Ayhan, Ali
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2023
• Subjects: Adjuvant treatment; Cervical cancer; Combined Modality Therapy; Female; GOG criteria; Humans; Hysterectomy; Intermediate risk; Medicin och hälsovetenskap; Neoplasm Staging; Prognosis; Radial surgery; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Uterine Cervical Neoplasms - pathology; Radial surgery; Radiotherapy; Cervical cancer; GOG criteria; Adjuvant treatment; Intermediate risk

The “intermediate-risk” (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuva...